- Oct 09 2014
PDS Biotechnology, a clinical stage immunotherapeutics company developing the powerful Versamune® nanoparticle technology, is delighted to announce that Sir Richard Sykes has accepted an invitation to join the company’s board of directors as Executive Chairman
North Brunswick, NJ—Also joining PDS’s board at this time are Mr. De Lyle Bloomquist, President, Global Chemicals Business for Tata Chemicals Ltd. and President, CEO and Director of Tata Chemicals North America Inc.; Michael Boyce-Jacino, PhD, Executive Director of NetScientific and CEO of QLIDA; and Mr. Greg Freitag, General Counsel, Senior Vice President of Business Development, Ex-CFO and current Director of AxoGen, Inc.
“PDS is pleased to welcome such an exceptional and successful group of pharmaceutical and business leaders to its board,” said Dr. Frank Bedu-Addo, CEO of PDS. “Our new board members’ deep experience in our industry will be crucial as PDS continues to progress its clinical trial and partnership activities towards commercialization.”